Franklin Resources’s MoonLake Immunotherapeutics MLTX Stock Holding History

Franklin Resources’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33,577	Closed	-$241K	–	3213
2025 Q3	$241K	Buy	+33,577	New	+$1.75M	﹤0.01%	2757
2025 Q2	–	Sell	-191,500	Closed	-$7.48M	–	3093
2025 Q1	$7.48M	Buy	+191,500	New	+$8.25M	﹤0.01%	1201
2023 Q4	–	Sell	-212,773	Closed	-$12.1M	–	2684
2023 Q3	$12.1M	Buy	212,773 +12,773	+6%	+$705K	0.01%	868
2023 Q2	$10.2M	Buy	+200,000	New	+$5.38M	﹤0.01%	912

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Franklin Resources's MLTX Position: Q4 2025 in Review

Franklin Resources sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 33,577 shares — an estimated $241K sold.

Franklin Resources first reported a position in MLTX in Q2 2023 and held it in 4 quarters. The position peaked at $12.1M in Q3 2023. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Franklin Resources reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Franklin Resources sold 33,577 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $241K.
Franklin Resources first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 4 quarters.
Franklin Resources's MoonLake Immunotherapeutics position peaked at $12.1M in Q3 2023.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Franklin Resources's 13F filing for Q4 2025, filed 11 Feb 2026.